However, in this study, linagliptin did not reverse the lipodystrophy induced by OSI-906 administration, implying that linagliptin exerts its effect on OSI-906-induced hepatic steatosis without altering either hepatic insulin signaling or insulin signaling in adipose tissue. The gene discussed is INS; the disease is fatty liver disease.